Loading
A phase 2 trial of Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by Replimune, Inc., active and no longer recruiting.
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) is a phase 2 interventional study registered as NCT03767348 by Replimune, Inc., with 340 participants planned, started 2017-09-20 and due to reach its primary completion in 2028-06. Interventions recorded: RP1, nivolumab. Conditions listed: Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Replimune, Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Replimune, Immune checkpoint inhibitors.
Shares Replimune, Melanoma, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/